Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme 1 selected

Guidance programme

Showing 411 to 420 of 797

TitleReference numberPublishedLast updated
Lanadelumab for preventing recurrent attacks of hereditary angioedemaTA606
Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoeaTA605
Idelalisib for treating refractory follicular lymphomaTA604
Lenalidomide with bortezomib and dexamethasone for untreated multiple myeloma (terminated appraisal)TA603
Pomalidomide with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)TA602
Benralizumab for treating severe eosinophilic asthmaTA565
Risankizumab for treating moderate to severe plaque psoriasisTA596
Brentuximab vedotin for untreated advanced Hodgkin lymphoma (terminated appraisal)TA594
Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancerTA595
Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitisTA590

Results per page

  1. 10
  2. 25
  3. 50
  4. All